National Cancer Institute; Notice of Meeting, 3830 [2022-01329]

Download as PDF 3830 Federal Register / Vol. 87, No. 16 / Tuesday, January 25, 2022 / Notices Health, 6701 Rockledge Drive, Bethesda, MD 20782, 301–402–4788, sarita.sastry@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) January 19, 2022. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–01358 Filed 1–24–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting AGENCY: National Institutes of Health, HHS. ACTION: Notice. The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on March 8, 2022. The topic for this meeting will be ‘‘Opportunities for Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.’’ The meeting is open to the public. DATES: The meeting will be held on March 8, 2022 from 8:30 a.m. to 4:45 p.m. EDT. ADDRESSES: The meeting will be held via an online video conferencing platform. Virtual attendance for the meeting will be accessible to members of the public who register at https:// www.scgcorp.com/dmicc2022/ Registration at least 5 days prior to the workshop. FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, including a draft agenda, which will be posted when available, see the DMICC website, www.diabetescommittee.gov, or contact Dr. William Cefalu, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, Bethesda, MD 20892, telephone: 301–435–1011; email: dmicc@mail.nih.gov. SUPPLEMENTARY INFORMATION: In accordance with 42 U.S.C. 285c–3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and comprising members of the Department of Health and Human Services and other khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:19 Jan 24, 2022 Jkt 256001 federal agencies that support diabetesrelated activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The March 8, 2022 DMICC meeting will focus on ‘‘Opportunities for Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.’’ Any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, there will not be time on the agenda for oral comments from members of the public. Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC website, www.diabetescommittee.gov. Dated: January 19, 2022. Bruce Tibor Roberts, Executive Secretary, DMICC, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. [FR Doc. 2022–01345 Filed 1–24–22; 8:45 am] BILLING CODE 4140–01–P Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee. Date: March 16, 2022. Time: 12:00 p.m. to 3:00 p.m. Agenda: Strategic Discussion of NCI’s Clinical and Translational Research Programs. Place: National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director, Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850, 240–276–6173, prindivs@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 19, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–01329 Filed 1–24–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee. The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov). PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 87, Number 16 (Tuesday, January 25, 2022)]
[Notices]
[Page 3830]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01329]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Institute Clinical Trials and Translational Research Advisory 
Committee.
    The meeting will be held as a virtual meeting and is open to the 
public. Individuals who plan to view the virtual meeting and need 
special assistance or other reasonable accommodations to view the 
meeting, should notify the Contact Person listed below in advance of 
the meeting. The meeting will be videocast and can be accessed from the 
NIH Videocasting and Podcasting website (https://videocast.nih.gov).

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee.
    Date: March 16, 2022.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: Strategic Discussion of NCI's Clinical and Translational 
Research Programs.
    Place: National Cancer Institute, 9609 Medical Center Drive, 
Rockville, MD 20850 (Virtual Meeting).
    Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director, 
Coordinating Center for Clinical Trials, National Cancer Institute, 
National Institutes of Health, 9609 Medical Center Drive, Room 
6W136, Rockville, MD 20850, 240-276-6173, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: January 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01329 Filed 1-24-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.